Core Viewpoint - The announcement indicates a reduction in shareholding by Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. in the company, which does not affect the control structure or governance of the company [1] Group 1: Shareholding Changes - Shanghai Zhangjiang Biopharmaceutical Base Development Co., Ltd. reduced its shareholding from 11,020,753 shares to 9,610,957 shares [1] - The percentage of total share capital held by Zhangjiang decreased from 7.82% to 6.82% [1] - The reduction involved a sale of 1,409,796 shares through a centralized bidding transaction, and the plan has been fully implemented [1] Group 2: Impact on Company Structure - The shareholding change does not trigger a mandatory tender offer [1] - There will be no change in the company's controlling shareholder or actual controller [1] - The governance structure and ongoing operations of the company will not be significantly impacted [1]
益诺思：上海张江生物医药基地开发有限公司持股比例已降至6.82%